Malaguido Marcus Rudolph, Casella Antonio Marcelo Barbante, Malaguido Daniela Rossetto Garcia
Programa de Pós-graduação Strictu-Sensu em Medicina e Ciências da Saúde, Universidade Estadual de Londrina, Londrina, PR, Brazil.
Arq Bras Oftalmol. 2007 Sep-Oct;70(5):814-22. doi: 10.1590/s0004-27492007000500016.
To describe the evolution of a series of cases of diffuse unilateral subacute neuroretinitis (DUSN) treated with albendazole.
Interventional case series. The authors developed a non-randomized clinical trial protocol to investigate the clinical evolution of diffuse unilateral subacute neuroretinitis cases treated with albendazole. According to protocol criteria up to now, six patients were selected that will be described separately.
Of the six studied patients, four presented the worm. All six patients treated with the antiparasitic drug showed improvement of visual acuity and of chorioretinal scars. During the weeks of treatment, evidence of worm inactivation was documented for the four patients with visible worms. No adverse drug side effects were observed.
The antiparasitic drug albendazole seems to be beneficial and safe in patients with diffuse unilateral subacute neuroretinitis. More studies are necessary to evaluate the effectiveness of albendazole in the treatment of diffuse unilateral subacute neuroretinitis.
描述一系列接受阿苯达唑治疗的弥漫性单侧亚急性神经视网膜炎（DUSN）病例的病情演变。
干预性病例系列研究。作者制定了一项非随机临床试验方案，以研究接受阿苯达唑治疗的弥漫性单侧亚急性神经视网膜炎病例的临床病情演变。根据目前的方案标准，选取了6例患者，将分别进行描述。
在6例研究患者中，有4例发现了虫体。所有6例接受抗寄生虫药物治疗的患者视力和脉络膜视网膜瘢痕均有改善。在治疗的数周内，4例发现可见虫体的患者有虫体失活的证据。未观察到药物不良反应。
抗寄生虫药物阿苯达唑似乎对弥漫性单侧亚急性神经视网膜炎患者有益且安全。需要更多研究来评估阿苯达唑治疗弥漫性单侧亚急性神经视网膜炎的有效性。
